Cargando…
Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody
Immunotherapy targeting aggregated alpha-synuclein (αSYN) is a promising approach for the treatment of Parkinson’s disease. However, brain penetration of antibodies is hampered by their large size. Here, RmAbSynO2-scFv8D3, a modified bispecific antibody that targets aggregated αSYN and binds to the...
Autores principales: | Roshanbin, Sahar, Julku, Ulrika, Xiong, Mengfei, Eriksson, Jonas, Masliah, Eliezer, Hultqvist, Greta, Bergström, Joakim, Ingelsson, Martin, Syvänen, Stina, Sehlin, Dag |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318263/ https://www.ncbi.nlm.nih.gov/pubmed/35890306 http://dx.doi.org/10.3390/pharmaceutics14071412 |
Ejemplares similares
-
Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis
por: Julku, Ulrika, et al.
Publicado: (2022) -
Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease
por: Gustavsson, Tobias, et al.
Publicado: (2023) -
PET Imaging in Preclinical Anti-Aβ Drug Development
por: Syvänen, Stina, et al.
Publicado: (2022) -
Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
por: Faresjö, Rebecca, et al.
Publicado: (2021) -
Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition
por: Meier, Silvio R., et al.
Publicado: (2018)